Sign In
Buy HEPA
$0.0600
-0.0030 (-4.76%)
At Close: Jun 03, 2026
Inventiva S A : Information financière du 1er semestre 2020 | Zone bourse
04:30pm, Monday, 06'th Jul 2020Information financière du 1er semestre 2020
04:30pm, Monday, 06'th Jul 2020
Trésorerie et équivalents de trésorerie à 52,2 M€ au 30 juin 2020
Daix (France), le 6 juillet 2020 - Inventiva (Euronext : IVA), société biopharmaceutique spécialisée dans le déve
A la suite des effets plus importants que prévus concernant la réduction de la stéatose lors de l'étude de Phase IIb NATIVE dans la NASH, le...
89bio (ETNB) Receives a Buy from Oppenheimer - Markets
10:56am, Thursday, 02'nd Jul 2020
Oppenheimer analyst Jay Olson maintained a Buy rating on 89bio (ETNB – Research Report) today and set a price target
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
12:00am, Thursday, 02'nd Jul 2020
Regulatory News: ABIONYX Pharma (Paris:ABNX): Market: Euronext Paris, Compartment C ISIN code: FR0012616852 Date Number of shares outstanding Total vo
Should You Throw in the Towel on Intercept Pharmaceuticals After Its Big Setback? | The Motley Fool
11:02am, Wednesday, 01'st Jul 2020
An approval pathway for OCA in treating NASH still exists. But it appears to be a steeper path.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc.
GENFIT : Résultats de l'assemblée générale ordinaire du 30 juin 2020 | Zone bourse
08:05pm, Tuesday, 30'th Jun 2020Analysts Are Downgrading Intercept Pharmaceuticals. Here’s Why.
03:53pm, Tuesday, 30'th Jun 2020
Uncertainty over its NASH drug weighs on the stock.
ENDRA Life Sciences Submits 510(k) Application to the US FDA for TAEUS(R) Liver Device | | IT Business Net
03:11pm, Tuesday, 30'th Jun 2020
Regulatory submission marks another major step toward commercialization of TAEUS liver device in 2020 ANN ARBOR, MI / ACCESSWIRE / June 30, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:
Grassley Says Talks On Drug Pricing Bill Are Broken, Pledges To Push GOP Bill Through Senate
01:03pm, Tuesday, 30'th Jun 2020
The Iowa senator’s comments could signal that there is little chance for a bill this year that would rein in drug prices, a policy that voters have expressed keen interest in.
Hepion Pharmaceuticals: CRV431 Continues To Progress In Early Phase NASH Clinical Trials
10:25am, Tuesday, 30'th Jun 2020
Hepion's drug, CRV431, has demonstrated safety and tolerability in Phase 1 clinical studies. It is now entering Phase 2a for NASH, which represents a $10 billio
Intercept CEO lays into FDA after NASH drug rejection -
09:48am, Tuesday, 30'th Jun 2020
Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection.
Legend Biotech (NASDAQ:PLRX) Now Covered by Analysts at Piper Sandler
04:32am, Tuesday, 30'th Jun 2020
Piper Sandler assumed coverage on shares of Legend Biotech (NASDAQ:PLRX) in a research note issued to investors on Monday morning, BenzingaRatingsTable reports. The brokerage issued an overweight rati
LOS ANGELES--(BUSINESS WIRE)--$ICPT #fraud--Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announced that it has commenced an investigation on
